Drug Trial Radar · NCT07091929
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jan 20, 2025
Primary completion
Jul 18, 2025
Study completion Jul 18, 2025
Sponsor
- Lead sponsor
- Beijing Sungen Biomedical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The research study is being done to see if SGC001 can be used to treat people scheduled to undergo percutaneous coronary intervention for Anterior ST-segment Elevation Myocardial Infarction. SGC001 might reduce the infarct size and inhibited inflammation, thereby preventing the incidence of major adverse cardiovascular events(MACE) events. Participants will either get SGC001 (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting SGC001 or placebo is the same. The participant was administered intravenously once. SGC001 is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe.
Conditions
- Anterior Myocardial Infarction
Interventions
SGC001Drug
The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.
PlaceboDrug
The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AE), Serious adverse events (SAE)Time frame: From randomisation to end-of-study (up to 30 days)
- Recommended Phase 2 dose (RP2D)Time frame: From randomisation to end-of-study (up to 30 days)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital Capital Medical University
Beijing, Beijing Municipality, China
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Linfen Central Hospital
Linfen, Shanxi, China
Teda International Cardiovascular Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.